MINNEAPOLIS , Sept. 06, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on
applying artificial intelligence to personalized medicine and drug discovery, is pleased to announce the formation of a new
Scientific Advisory Board, with Marc Malandro appointed as its first member. The Scientific Advisory Board will be comprised of
world-renowned scientific and medical experts, who will work closely with Precision Therapeutics’ senior management team to advance
the company's growth strategy in the precision medicine market.
Marc Malandro PhD, CLP, RTTP, is Vice President of Operations for Science at the Chan Zuckerberg Initiative. Prior to his
position, Dr. Malandro was the founding director of the Innovation Institute and Vice Chancellor for Technology Management and
Commercialization at the University of Pittsburgh. Dr. Malandro was responsible for leading the combination of the Office of
Technology Management, the Office of Enterprise Development and the Institute for Entrepreneurial Excellence forming the Pitt
Innovation Institute in 2013. Prior to The University of Pittsburgh, Dr. Malandro, who has a doctoral degree in biochemistry and
molecular biology from the University of Florida, co-founded Sagres Discovery, a California-based systems biology company focused
on the understanding of the molecular basis of cancer. Dr. Malandro is also on the Advisory Board for Helomics Corporation.
Dr. Carl Schwartz, Chief Executive Officer of Precision Therapeutics, commented, “We have decided to put together a Scientific
Advisory Board of medical and scientific experts to guide Precision Therapeutics as it repositions itself as a provider of advanced
solutions to the precision medicine market. Marc’s deep understanding of molecular biology and the transformative impact that
precision medicine is having on oncology will be invaluable as we provide clinical testing for cancer patients, work to improve the
effectiveness of current cancer treatments and help design new therapies for the future.”
Over the next few weeks, the Company will be announcing the appointment of additional industry leaders to its Scientific
Advisory Board.
To be added to the Precision Therapeutics’ database, please email Info@MoneyInfo-llc.com with your email address. This is solely for the use of
Precision Therapeutics and will not be sold or distributed to third parties.
About Precision Therapeutics Inc.
Precision Therapeutics (NASDAQ:AIPT) operates in two business areas: first, applying artificial intelligence to
personalized medicine and drug discovery to provide personalized medicine solutions for patients and clinicians as well as clients
in the pharmaceutical, diagnostic, and biotech industries, and second, production of the FDA-approved STREAMWAY® System for
automated, direct-to-drain medical fluid disposal. For additional information, please visit www.precisiontherapeutics.com.
Precision Therapeutics’ medicine business is committed to improving the effectiveness of cancer therapy using the power of
artificial intelligence (AI) applied to rich data diseases databases. This business has launched with Precision
Therapeutics' investment in Helomics Corporation, a precision medicine company and integrated clinical contract research
organization whose mission is to improve patient care by partnering with pharmaceutical, diagnostic, and academic organizations to
bring innovative clinical products and technologies to the marketplace. In addition to its proprietary precision diagnostics
for oncology, Helomics offers boutique CRO services that leverage their patient-derived tumor models, coupled to a wide range of
multi-omics assays (genomics, proteomics and biochemical), and a proprietary bioinformatics platform (D-CHIP) to provide a tailored
solution to our client's specific needs. Helomics is 25% owned by Precision Therapeutics. Helomics® is headquartered
in Pittsburgh, Pennsylvania where the company maintains state-of-the-art, CLIA-certified, clinical and research
laboratories. For more information, please visit www.Helomics.com.
Precision Therapeutics has also announced the formation of a subsidiary, TumorGenesis to pursue a new rapid approach to
growing tumors in the laboratory, which essentially “fools” the cancer cells into thinking they are still growing inside the
patient. Precision Therapeutics and Helomics have also announced a proposed joint venture with GLG Pharma focused on
using their combined technologies to bring personalized medicines and testing to ovarian and breast cancer patients, especially
those who present with ascites fluid (over one-third of patients). The growth strategy in this business includes securing new
partnerships and considering acquisitions in the precision medicine space.
Sold through the Skyline Medical business of Precision Therapeutics, The STREAMWAY System virtually eliminates staff
exposure to blood, irrigation fluid and other potentially infectious fluids found in the healthcare environment. Antiquated manual
fluid handling methods that require hand carrying and emptying filled fluid canisters present an exposure risk and potential
liability. Skyline Medical's STREAMWAY System fully automates the collection, measurement, and disposal of waste fluids and is
designed to: 1) reduce overhead costs to hospitals and surgical centers; 2) improve compliance with OSHA and other
regulatory agency safety guidelines; 3) improve efficiency in the operating room, and radiology and endoscopy departments, thereby
leading to greater profitability; and 4) provide greater environmental stewardship by helping to eliminate the approximately 50
million potentially disease-infected canisters that go into landfills each year in the U.S. For additional information,
please visit www.skylinemedical.com.
Forward-looking Statements
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and
uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements
made herein. Such risks and uncertainties include (1) risks related to the proposed merger, including the fact that we may not
complete the merger; we do not have complete information about Helomics; the combined company will not be able to continue
operating without additional financing; possible failure to realize anticipated benefits of the merger; costs associated with the
merger may be higher than expected; the merger may result in disruption of the Company’s and Helomics’ existing businesses,
distraction of management and diversion of resources; delay in completion of the merger may significantly reduce the expected
benefits; and the market price of the Company’s common stock may decline as a result of the merger; (2) risks related to our
partnerships with other companies, including the need to negotiate the definitive agreements; possible failure to realize
anticipated benefits of these partnerships; and costs of providing funding to our partner companies, which may never be repaid or
provide anticipated returns; and (3) other risks and uncertainties relating to the Company that include, among other things,
current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further
financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than
expected sales and revenues; sales cycles that can be longer than expected, resulting in delays in projected sales or failure to
make such sales; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further
market acceptance, if our product is not accepted by our potential customers, it is unlikely that we will ever become profitable;
adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial
condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our
ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to
possibly license from others patents and patent applications necessary to develop products; the Company's ability to implement its
long range business plan for various applications of its technology; the Company's ability to enter into agreements with any
necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition, the
obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and
management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with
the Securities and Exchange Commission, which are available for review at www.sec.gov. This is not a solicitation to buy or sell securities and does not purport to
be an analysis of the Company's financial position. See the Company's most recent Annual Report on Form 10-K, and subsequent
reports and other filings at www.sec.gov.
Contacts:
Investor Relations
KCSA Strategic Communications
Elizabeth Barker
(212) 896-1203
ebarker@kcsa.com
MONEYINFO, LLC
Charles Moskowitz
617-827-1296
info@moneyinfo-llc.com